Literature DB >> 10322563

[Increasing the immunization rate against measles, mumps, and rubella in medical students at the University of Berne].

D Germann1, L Matter.   

Abstract

From 1992 to 1997 the seroprevalence of antibodies against measles, mumps and rubella (MMR) in Swiss medical students was between 77.3% and 86.2%, which is clearly below the target of > 95%. To prevent MMR infections in doctors and possible transmission to their patients, in 1994 we started a project in which MMR vaccination was offered to non-immune students. During three courses in medical school, 82 of 87 (94.3%) non-immune students were vaccinated, thus increasing the immunization rate to more than 96%. We have developed a spread sheet allowing calculation of the direct costs of two different strategies: 1. Determination of immunity followed by MMR vaccination of non-immune students; 2. Universal MMR immunization. Screening before vaccination was less expensive if the immunity level was higher than 73.5% and the calculation was based on prices for mass screening and mass vaccination. Universal immunization was favoured when prices for individual antibody determinations and vaccinations were used for the calculation. A targeted programme of MMR vaccination was successful in increasing the immunization rate of medical students against MMR to > 96%.

Entities:  

Mesh:

Year:  1999        PMID: 10322563

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  2 in total

1.  Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, polio, HBV, HCV and HIV) in medical students.

Authors:  Sabine Wicker; Holger F Rabenau; René Gottschalk; Hans Wilhelm Doerr; Regina Allwinn
Journal:  Med Microbiol Immunol       Date:  2007-02-02       Impact factor: 3.402

2.  Reliability of medical students' vaccination histories for immunisable diseases.

Authors:  Sabine Wicker; Regina Allwinn; René Gottschalk; Holger F Rabenau
Journal:  BMC Public Health       Date:  2008-04-15       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.